Cara Therapeutics, Inc. (CARA): Price and Financial Metrics


Cara Therapeutics, Inc. (CARA): $12.00

-0.27 (-2.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CARA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CARA POWR Grades

  • CARA scores best on the Value dimension, with a Value rank ahead of 63.21% of US stocks.
  • CARA's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • CARA ranks lowest in Stability; there it ranks in the 17th percentile.

CARA Stock Summary

  • The ratio of debt to operating expenses for CARA THERAPEUTICS INC is higher than it is for about only 6.62% of US stocks.
  • Over the past twelve months, CARA has reported earnings growth of -475.15%, putting it ahead of only 3.5% of US stocks in our set.
  • As for revenue growth, note that CARA's revenue has grown -70.64% over the past 12 months; that beats the revenue growth of just 2.38% of US companies in our set.
  • Stocks that are quantitatively similar to CARA, based on their financial statements, market capitalization, and price volatility, are PRTA, AEVA, CUE, CCCC, and ONCT.
  • Visit CARA's SEC page to see the company's official filings. To visit the company's web site, go to www.caratherapeutics.com.

CARA Valuation Summary

  • CARA's price/sales ratio is 16.1; this is 215.69% higher than that of the median Healthcare stock.
  • Over the past 109 months, CARA's price/sales ratio has gone down 7.5.

Below are key valuation metrics over time for CARA.

Stock Date P/S P/B P/E EV/EBIT
CARA 2023-01-20 16.1 3.4 -7.2 -6.7
CARA 2023-01-19 15.6 3.3 -6.9 -6.5
CARA 2023-01-18 14.9 3.2 -6.6 -6.2
CARA 2023-01-17 14.6 3.1 -6.5 -6.0
CARA 2023-01-13 14.8 3.2 -6.6 -6.1
CARA 2023-01-12 14.4 3.1 -6.4 -5.9

CARA Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 45.55%.
  • Its year over year net income to common stockholders growth rate is now at -762.03%.
  • Its 5 year net income to common stockholders growth rate is now at -64.75%.
Over the past 33 months, CARA's revenue has gone up $19,541,000.

The table below shows CARA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 39.427 -56.465 -88.517
2022-06-30 48.886 -45.389 -66.35
2022-03-31 25.883 -61.891 -92.889
2021-12-31 23.028 -60.087 -88.441
2021-09-30 134.296 23.246 23.85
2021-06-30 123.29 15.742 8.354

CARA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CARA has a Quality Grade of C, ranking ahead of 32.88% of graded US stocks.
  • CARA's asset turnover comes in at 0.554 -- ranking 69th of 682 Pharmaceutical Products stocks.
  • APLS, FENC, and FSTX are the stocks whose asset turnover ratios are most correlated with CARA.

The table below shows CARA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.554 1 0.046
2021-03-31 0.616 1 0.091
2020-12-31 0.690 1 0.059
2020-09-30 0.148 1 -0.840
2020-06-30 0.112 1 -0.773
2020-03-31 0.112 1 -0.754

CARA Price Target

For more insight on analysts targets of CARA, see our CARA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.33 Average Broker Recommendation 1.44 (Moderate Buy)

CARA Stock Price Chart Interactive Chart >

Price chart for CARA

CARA Price/Volume Stats

Current price $12.00 52-week high $13.97
Prev. close $12.27 52-week low $7.40
Day low $11.99 Volume 237,500
Day high $12.44 Avg. volume 359,639
50-day MA $11.24 Dividend yield N/A
200-day MA $10.11 Market Cap 644.81M

Cara Therapeutics, Inc. (CARA) Company Bio


Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. The company was founded in 2004 and is based in Shelton, Connecticut.


CARA Latest News Stream


Event/Time News Detail
Loading, please wait...

CARA Latest Social Stream


Loading social stream, please wait...

View Full CARA Social Stream

Latest CARA News From Around the Web

Below are the latest news stories about CARA THERAPEUTICS INC that investors may wish to consider to help them evaluate CARA as an investment opportunity.

Cara Therapeutics (CARA) Presents At 41st Annual Healthcare Conference - Slideshow (NASDAQ:CARA)

The following slide deck was published by Cara Therapeutics, Inc.

Seeking Alpha | January 20, 2023

Cannabis Stock Gainers And Losers From January 19, 2023

GAINERS: HEXO (NASDAQ: HEXO ) shares closed up 12.88% at $1.49 Charlottes Web Holdings (OTC: CWBHF ) shares closed up 4.81% at $0.57 Cara Therapeutics (NASDAQ: CARA ) shares closed up 4.76% at $11.44 Cipher Pharmaceuticals (OTC: CPHRF ) shares closed up 4.07% at $2.81 LOSERS: Innovative Ind Props (NYSE: IIPR ) shares closed down 16.93% at $92.11 iAnthus Capital Hldgs (OTC: ITHUF ) shares … Full story available on Benzinga.com

Benzinga | January 19, 2023

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host an in-person and virtual Capital Markets Day in New York City on Thursday, February 16, 2023, from 10:00 a.m. to 1:00 p.m. EST. The event will highlight the launch of KORSUVA® (difelikefalin) injection and feature presentations during

Yahoo | January 17, 2023

ILMN, CARA and ADMA are among after hour movers

Gainers: CureVac (CVAC) +9%. Cara Therapeutics (CARA) +5%

Seeking Alpha | January 6, 2023

Cara Therapeutics, Inc. (CARA) Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference…

Marijuana Stocks | January 3, 2023

Read More 'CARA' Stories Here

CARA Price Returns

1-mo 11.73%
3-mo 27.66%
6-mo 38.09%
1-year 8.79%
3-year -25.00%
5-year -20.32%
YTD 11.73%
2022 -11.82%
2021 -19.50%
2020 -6.08%
2019 23.92%
2018 6.21%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8775 seconds.